As CD36 transcription is regulated by Ppar-γ and its co-receptor and Ppar-γ agonists have already been approved for the treatment of Type 2 diabetes, the authors tested the effect of rosiglitazone on malaria infection. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.